BridgeMD
Tests treatment safety and results for Lung Cancer
Official title Safety and Efficacy Evaluation of Cryoablation in the Treatment of Ground-Glass Nodules
ClinicalTrials.gov ID: NCT07232433
What this study is testing
- What it's testing
- Lung cancer is the leading cause of cancer-related mortality worldwide, making early diagnosis and intervention critical. With the widespread adoption of low-dose computed tomography (LDCT) screening, the detection rate of pulmonary ground-glass nodules (GGNs) has increased significantly.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years.
- Malignancy confirmed by histopathology or multidisciplinary team (MDT) discussion. For a solitary GGN: size between 6-30 mm. For multiple GGNs: each...
- Patient is ineligible for or unwilling to undergo video-assisted thoracoscopic surgery (VATS).
- Patient is ineligible for or declines radiotherapy or stereotactic body radiotherapy (SBRT).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
You likely can't join if
- Presence of severe cardiac, pulmonary, hepatic, or renal dysfunction, rendering the patient ineligible for general anesthesia.
- Contraindication to either bronchoscopy or computed tomography (CT)-guided percutaneous puncture.
- High risk associated with percutaneous puncture for at least one target lesion, or absence of a feasible access route as determined by pre-procedural...
- Platelet count \ 18 seconds, or prothrombin activity \< 40%).
- Concurrent participation in another treatment clinical trial, or anticipation of requiring additional antitumor therapy outside the scope of this...
- Any other condition deemed by the investigator to render the patient unsuitable for study participation.
See the full eligibility criteria
- Age ≥ 18 years.
- Malignancy confirmed by histopathology or multidisciplinary team (MDT) discussion. For a solitary GGN: size between 6-30 mm. For multiple GGNs: each measuring 6-30 mm, with no more than 3 nodules deemed to require...
- Patient is ineligible for or unwilling to undergo video-assisted thoracoscopic surgery (VATS).
- Patient is ineligible for or declines radiotherapy or stereotactic body radiotherapy (SBRT).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- The subject demonstrates good compliance and has voluntarily provided written informed consent to participate.
- Presence of severe cardiac, pulmonary, hepatic, or renal dysfunction, rendering the patient ineligible for general anesthesia.
- Contraindication to either bronchoscopy or computed tomography (CT)-guided percutaneous puncture.
- High risk associated with percutaneous puncture for at least one target lesion, or absence of a feasible access route as determined by pre-procedural bronchoscopic path planning.
- Platelet count \ 18 seconds, or prothrombin activity \< 40%).
- Concurrent participation in another treatment clinical trial, or anticipation of requiring additional antitumor therapy outside the scope of this study during the trial period.
- Any other condition deemed by the investigator to render the patient unsuitable for study participation.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.